Title:
COMPOSITIONS AND METHODS OF USING A HUMANIZED ANTI-DKK2 ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2021/003687
Kind Code:
A1
Abstract:
Provided herein is the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, provided herein are methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods is provided.
Inventors:
SUN LE (CN)
Application Number:
PCT/CN2019/095362
Publication Date:
January 14, 2021
Filing Date:
July 10, 2019
Export Citation:
Assignee:
UNIV YALE (US)
SUN LE (CN)
SUN LE (CN)
International Classes:
A61K39/395; A61P35/00; C07K16/00; C07K16/18; C12Q1/6886; G01N33/68
Domestic Patent References:
| WO2017074774A1 | 2017-05-04 | |||
| WO2018174984A1 | 2018-09-27 | |||
| WO2016126098A1 | 2016-08-11 | |||
| WO2010029288A2 | 2010-03-18 |
Foreign References:
| EP2218735A1 | 2010-08-18 | |||
| US20180200354A1 | 2018-07-19 |
Other References:
XIAO，Q.ET AL.: "DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation", NATURE MEDICINE, vol. 24, no. 3, 12 February 2018 (2018-02-12), pages 262 - 270, XP055463828, DOI: 20200317142042X
ZHANG，Y.ET AL.: "Expression and Regulation of Dickkopf2 During Periimplantation in Mice", JOURNAL OF REPRODUCTION AND DEVELOPMENT, vol. 55, no. 1, 8 August 2008 (2008-08-08), pages 17 - 22, XP055772545, DOI: 20200317142001X
MIN，J.ET AL.: "The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 5, 31 May 2011 (2011-05-31), pages 1882 - 1893, XP055463595, DOI: 20200317142520A
SHEN，T.ET AL.: "Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells", CELL DEATH DISCOVERY, vol. 5, 31 July 2019 (2019-07-31), pages 1 - 12, XP055772546, DOI: 20200317142805A
See also references of EP 3996745A4
ZHANG，Y.ET AL.: "Expression and Regulation of Dickkopf2 During Periimplantation in Mice", JOURNAL OF REPRODUCTION AND DEVELOPMENT, vol. 55, no. 1, 8 August 2008 (2008-08-08), pages 17 - 22, XP055772545, DOI: 20200317142001X
MIN，J.ET AL.: "The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 5, 31 May 2011 (2011-05-31), pages 1882 - 1893, XP055463595, DOI: 20200317142520A
SHEN，T.ET AL.: "Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells", CELL DEATH DISCOVERY, vol. 5, 31 July 2019 (2019-07-31), pages 1 - 12, XP055772546, DOI: 20200317142805A
See also references of EP 3996745A4
Attorney, Agent or Firm:
JEEKAI & PARTNERS (CN)
Download PDF:
Previous Patent: HIGH-SPEED LANDSLIDE IMPACT SIMULATION DEVICE
Next Patent: TRIAXIAL EXPERIMENT DEVICE FOR HYDRATE
Next Patent: TRIAXIAL EXPERIMENT DEVICE FOR HYDRATE